We reexamined the attributable mortality of nosocomial candidemia 15 years after a retrospective cohort study performed at our hospital demonstrated an attributable mortality of 38%. For all episodes of nosocomial candidemia between 1 July 1997 and 30 June 2001, we matched control patients with case patients by age, sex, date of hospital admission, underlying disease(s), length of time at risk, and surgical procedure(s). We analyzed 108 matched pairs. There were no statistically significant differences in age, sex, underlying disease(s), time at risk, surgical procedure, or vital signs at admission between cases and controls. The crude mortality among case patients was 61% (66 of 108 patients), compared with 12% (13 of 108) among control patients, for an attributable mortality of 49% (95% CI, 38%-60%). Nosocomial candidemia is still associated with an extremely high crude and attributable mortality-much higher than that expected from underlying disease alone.
phylaxis has decreased the incidence of invasive infections with Candida species in some populations (e.g., bone marrow transplant recipients [4, 5] ). Conversely, increased azole use may be associated with the emergence of azole-resistant Candida albicans or a shift in species distribution from a preponderance of C. albicans to more frequent isolation of Candida species that are less susceptible to azoles and polyenes, such as Candida glabrata [6] . In addition, newer antifungal agents provide additional options for the management of candidiasis [7, 8] . For these reasons, we decided to obtain a contemporary estimate of the attributable mortality of nosocomial candidemia by repeating a carefully matched retrospective cohort study.
PATIENTS AND METHODS

Setting.
UIHC is an 813-bed teaching hospital providing tertiary care for persons in the state of Iowa. More than 40,000 patients are admitted to UIHC each year. The UIHC is a level 1 trauma center, has 72 beds in intensive care units, and supports active bone marrow and solid-organ transplantation programs. Hospital stay before T 0 , a median days 13 13 COPD or other lung disease 20 25 Coronary artery disease 19 22 Congestive heart failure 13 16 Dialysis for chronic renal failure 5 3
Cirrhosis 9 8
Leukemia or lymphoma 18 23 Other malignancies 26 20 Infection (other than candidemia) 22 We defined nosocomial Candida BSI as at least 1 blood culture positive for Candida species for a patient who developed signs or symptoms of BSI 148 h after hospital admission. For all patients identified, we performed a detailed record review and abstracted data onto a data collection form for entry into a database (Access; Microsoft).
Selection of controls. We carefully matched each case patient with nosocomial candidemia to a control patient to assess the mortality and length of stay attributable to candidemia. Control selection and study design followed that described elsewhere [3] . We used a stepwise procedure to narrow a list of potential controls in 3 stages. First, we used computerized databases to generate lists of potential controls for each case, matching by age within 10 years, sex, length of time at risk (that is, the length of stay for each control was at least as long as the time from hospital admission to onset of candidemia for the matched case), and primary diagnosis at admission. Second, we reviewed codes in the International Classification of Diseases, Ninth Revision and computerized medical records to match for underlying disease(s), primary and secondary diagnoses, and surgical procedure(s). Finally, we performed manual review of candidate charts to identify the best possible match on the basis of severity and duration of illness, without knowledge of outcome for either case or control.
We also calculated the baseline Charlson comorbidity index for each case and control to further compare the severity of illness of cases with that of controls [9] . We defined a time "T 0 " as follows: for cases, T 0 was the time the first blood culture positive for Candida was obtained, and, for controls, T 0 was the time from admission of the control patient to the time at which the matched case patient had their first blood culture positive for Candida.
Microbiologic methods. We identified Candida species using Vitek and API products (bioMerieux) or conventional methods, as appropriate, and performed antifungal susceptibility testing with the reference broth microdilution method described by the NCCLS [10] . Interpretive susceptibility criteria for fluconazole were those published by the NCCLS. We tested Candida parapsilosis strain ATCC 22019 and Candida krusei strain ATCC 6258 with each run for quality control.
Statistical analysis. We defined the attributable mortality due to nosocomial candidemia as excess mortality due to candidemia, which was expressed as follows: [crude mortality of mortality of matched controls]. We calculated cases] Ϫ [crude the risk ratio for death by dividing the crude mortality rate for the cases by that for the controls. We compared categorical variables between case and control groups with the x 2 test or Fisher's exact test, as appropriate, and compared continuous variables with a paired Student's t test. We set a at 0.05, and all P values were 2-tailed. We performed statistical analyses using SAS, version 8.0 (SAS), and LogExact, version 4 (Cytel).
RESULTS
One hundred eight patients developed nosocomial candidemia between 1 July 1997 and 30 June 2001, for an overall rate of 1.4 episodes of candidemia per 10,000 patient-days. Candida organisms were the fourth leading cause of nosocomial BSI at UIHC during the study period, after coagulase-negative staph- [3] . Baseline characteristics of cases and controls. There were no significant differences in demographic characteristics and underlying illness variables between cases and controls (table 1), which indicates that the matching process was successful. In addition, the baseline mean Charlson comorbidity index did not differ between cases and controls (3.4 vs. 3.3, respectively;
). P p .6 Candida species distribution and fluconazole susceptibility. C. albicans was the predominant species; it was isolated in 63% of the episodes of candidemia (table 2) . Only 3 isolates (1 C. glabrata and 2 C. krusei isolates) were fluconazole resistant (R), although most C. glabrata tested were in the susceptibledose dependent (S-DD) category (MIC of fluconazole, 16-32 mg/mL; table 3).
Infection interval and treatment of cases. The median and mean intervals between admission and onset of candidemia were 13 and 20.8 days, respectively. Seventy cases (65%) received an amphotericin B preparation (deoxycholate-or lipidbased) sometime during treatment, 66 (61%) received fluconazole therapy, and 43 (40%) received some sequential combination of the two. More than one-half (56%) of case patients who received antifungal therapy received an amphotericin B preparation as initial therapy, and the remaining cases received fluconazole first. The mean duration of antifungal therapy was 16.5 days. Twelve of the 15 cases who never received antifungal therapy died, all but 1 within 72 h after T 0 (and before positive culture results were available).
Mortality and length of hospital stay. Sixty-six of the 108 cases died during hospitalization, for a crude mortality of 61%. Thirteen of the 108 controls died during hospitalization, for a crude mortality of 12%. The attributable mortality was therefore 49%, with a 95% CI of 38%-60%. Although the attributable mortality of nosocomial candidemia in this study was higher than that for 1983-1986, the 95% CIs of the estimates overlap (figure 1). We also used 30-day mortality as an end point. Fifty-two cases (48%) died within 30 days after T 0 , compared with 11 controls (10%), for a 30-day attributable mortality of 38%. Among those who died during hospitalization, the median time from T 0 to death was 9 days for cases and 13 days for controls . The risk ratio for death among cases, compared with that among controls, was 5.1 (95% CI, 2.9-8.6).
The crude mortality among cases did not differ significantly by Candida species or fluconazole susceptibility category. Crude mortality rates were 62% for C. albicans, 50% for C. glabrata, 46% for C. parapsilosis, and 70% for Candida tropicalis. All 4 case patients with candidemia due to Candida lusitaniae (2 case patients) and C. krusei (2 case patients) died during hospitalization. Two (66%) of 3 cases infected with fluconazole-R Candida species died, compared with 5 (50%) of 10 infected with fluconazole-S-DD Candida species and 59 (62%) of 95 infected only with fluconazole-susceptible Candida species. Of the 13 cases infected with fluconazole-nonsusceptible (R or S-DD) Candida species, 3 were treated only with fluconazole (1 received 800 mg/day and 2 received 400 mg/day). Only 1 of 3 who received "discordant" therapy died during hospitalization (after receiving only 2 days of fluconazole therapy [400 mg/ day]). The crude mortality among cases also did not differ significantly according to time of antifungal therapy initiation or antifungal agent. Of interest, 11 cases began receiving antifungal therapy before T 0 , 58 within 48 h after T 0 , and 39 at 148 h after T 0 (or not at all), with crude mortality rates of 64%, 59%, and 64%, respectively ( ). P p . 9 The median lengths of post-T 0 hospital stay among all cases and controls were 15.5 and 12.5 days, respectively; however, when only surviving matched pairs were examined, the median lengths of stay among the cases and controls were 26.5 and 16.0 days, respectively, with a difference of 10.5 days (table 4) . Differences in physiological variables. Physiological variables (body temperature, blood pressure, heart rate, and respiratory rate) for cases and controls were recorded at hospital admission, 72 h before T 0 , and at T 0 . No significant differences in values of physiological variables between cases and controls were noted at admission. At 72 h before T 0 and at T 0 , the mean heart rate and body temperature among cases were significantly higher than those among controls ( for each comparison; P ! .01 figure 2 ).
DISCUSSION
The crude and attributable mortality of nosocomial candidemia have not changed significantly from those reported at our hospital almost 2 decades ago [3] . The high crude mortality we found associated with nosocomial candidemia (61%) is consistent with previous studies, which report crude mortality rates of 40%-75% [2, [11] [12] [13] [14] [15] [16] [17] [18] [19] . The laborious matching process we used was intended to remove the confounding effect of underlying illness and to allow us to estimate the proportion of the mortality attributable to candidemia. Indeed, our control group had a crude mortality rate (12%) much higher than the overall crude mortality rate (2.5%) among patients admitted to acute care hospitals in the United States [20] . The high attributable mortality rate we found was, therefore, a result of the continued very high crude mortality rate among patients who acquire Candida BSI in the hospital.
It is noteworthy that the crude mortality rates we and others report are higher than those from randomized, controlled trials of therapy for invasive candidiasis [7, 21] . This illustrates the selected nature of the population meeting inclusion criteria for enrollment in clinical trials. The clinical response rates of 170% from randomized clinical trials cannot, therefore, be generalized to all hospitalized candidemic patients. Prospective clinical trials also estimate the mortality attributable to candidemia to be much lower than those observed with our retrospective cohort design (5%-7% [7, 21] vs. 38%-49% [3] ). Because these lower estimates are based on the presence of Candida organisms in the bloodstream within 48 h before death (or autopsy evidence of visceral candidiasis), they fail to include deaths among patients who clear their Candida infection but nonetheless die from causes related to the physiological insult sustained during infection.
Several previous retrospective cohort studies [3, [22] [23] [24] [25] have demonstrated a significant contribution of nosocomial BSI to overall or crude mortality rates (with attributable mortality rates ranging from 14% for coagulase-negative staphylococcal BSI [23] to 38% for candidemia [3] ). Some have criticized attributable mortality estimates from retrospective cohort studies, questioning whether all excess deaths among cases should be attributed to infection [26] . Indeed, the differences in crude and attributable mortality rates between 30-day and in-hospital end points in our study demonstrate that some deaths occur long after hospital admission and onset of candidemia.
The most important limitation of our study and others is an inability to control for the trajectory of illness course during hospitalization (but before infection) among cases versus that among controls. Nosocomial infections may occur as part of a complex, declining clinical course for which the end point is death, rather than as an interruption of an otherwise stable or improving clinical course. Despite efforts to control both for underlying illness at hospital admission and for length of time at risk for infection, we do not believe it is possible to completely control for dynamic changes in health status, at least among patients who are not in the intensive care unit and for whom sequential, detailed physiological assessment scores (e.g., APACHE II scores) are not available. Even with such data, matching on all important underlying illness variables, in addition to changes in physiological assessment scores over time, would severely limit and complicate control selection. Moreover, differences in clinical status before infection may represent incipient, unrecognized infection, rather than a decline in the health status of case patients due to other causes (especially in view of the limited sensitivity of blood cultures for detecting candidemia). For example, the greatest differences in vital signs between cases and controls was at T 0 . However, at 72 h before T 0 , the cases had higher temperatures and heart rates than did the controls, findings which we feel are consistent with incipient candidemia.
Whether all the deaths that we report as attributable to nosocomial candidemia were indeed attributable, or whether some were merely associated with candidemia, it is clear that nosocomial candidemia remains a devastating complication of health care delivery. This conclusion is supported by another study performed at our hospital, in which Pittet and colleagues [27] demonstrated Candida species to be the only organism group independently associated with mortality due to nosocomial BSI.
The persistently high mortality associated with candidemia does not appear to be related to an increase in in vitro antifungal resistance in our hospital. It is consistent with data from multicenter surveillance studies that C. albicans remains the most common cause of candidemia and that fluconazole resistance remains uncommon in bloodstream isolates of Candida species [28] . In addition, advances in antifungal therapy since the mid1980s, which primarily consist of the widespread use of fluconazole and lipid preparations of amphotericin B, have not had a significant impact on the crude or attributable mortality of nosocomial candidemia.
Our data suggest that prevention of candidemia should be the highest priority and is more likely to reduce mortality due to this devastating infection than is seeking advances in supportive care or antifungal therapy for patients who are already infected. Indeed, data from our hospital and from other investigators [4, 5] suggest that the use of fluconazole prophylaxis in high-risk populations (e.g., hematopoetic stem cell transplant recipients) may favorably affect the overall rate of candidemia. In addition, during the 1990s, when prophylaxis for selected high-risk groups began to be implemented more widely, the overall mortality rate attributable to invasive candidiasis decreased [29] . But, as our data demonstrate, patients who acquire candidemia are still very likely to die during hospitalization.
Prophylactic or preventive strategies for high-risk patients outside of selected groups (e.g., recipients of bone marrow and higher-risk liver transplants) have not been developed. Prevention strategies that hold promise include programs to improve use and placement of central venous catheters and care for recipients of such catheters [30, 31] , control of antibiotic use, and the development of decision rules that would allow clinicians to identify patients who would benefit from antifungal prophylaxis strategies [32] .
In summary, the crude and attributable mortality of nosocomial candidemia remain high-much higher than would be expected to result from underlying disease alone. We believe that improved measures to prevent nosocomial candidemia will decrease mortality more than will improved treatment regimens. Further investigation is needed to determine which highrisk populations may benefit from preemptive or prophylactic antifungal therapy to prevent this devastating infection [32] .
